Press for Actavis
Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Oxymorphone Hydrochloride Extended-Release Tablets, CII 7.5mg and 15mg, a generic equivalent of Opana ER®.
The 7.5mg and 15mg strength of Opana ER had U.S. total sales of approximately $21.9 million for the 12 months ending March 31, 2011, according to IMS Health.
Actavis Group has inaugurated a new expansion pharmaceutical manufacturing plant in Iceland. Actavis said the new site will not use fossil fuel in tablet manufacturing and packaging, generating zero carbon footprint.
Actavis is investing £850,000 in a promotional campaign for its cold sore brand Cymex. The Cymex campaign includes TV sponsorship, consumer press advertising and a PR campaign throughout the winter months, the company says.
Actavis has announced the launch of its First Resort range. The two initial products launched are Double Action Pain Relief, containing diclofenac, and Period Pain Reliever, containing naproxen.